Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
24/7 Wall St. on MSN5h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
There’s no specific recommended Mounjaro diet plan. A healthy diet with Mounjaro generally consists of fresh fruits and vegetables, whole grains, and lean proteins. Avoiding foods high in ...
A mom of two is getting her exercise by cleaning her house. It's something Melissa Floro says she didn't have the energy to ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback